Company: ACHV
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-059297
Chunk: 25

Company: ACHIEVE LIFE SCIENCES, INC.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 25
---
 subject to continued service as a director. • In January 2024, each director then seated received a grant of stock options to acquire 31,500 shares of common stock, with 100% vesting on the earlier of the eighteen-month anniversary of the grant date or the date immediately prior to our 2025 annual meeting of stockholders, subject to the grantee’s continued service as a director. Director Compensation Paid for 2024 The following table summarizes all compensation earned or awarded to non-employee directors who served during 2024 as compensation for board service during the 2024 fiscal year. Mr. King became an employee in August 2024 upon his appointment as Interim Executive Chairman, and Dr. Himes resigned as a Director in January 2025.

|                   |     | Fees Earned or 
 Paid in Cash   |        |     | Option Awards |         |     | Total |         |
| Name              |     | -$             |        |     | -$)(1)(2      |         |     | -$    |         |
| Stuart Duty       |     |                | 58,500 |     |               | 104,378 |     |       | 162,878 |
| Vaughn Himes      |     |                | 58,886 |     |               | 104,378 |     |       | 163,264 |
| Thomas B. King(3) |     |                | 50,126 |     |               | 104,378 |     |       | 154,504 |
| Bridget Martell   |     |                | 60,000 |     |               | 104,378 |     |       | 164,378 |
| Thomas Sellig     |     |                | 59,472 |     |               | 104,378 |     |       | 163,850 |

(1) The dollar amounts reflect the aggregate grant date fair value of equity awards granted within the fiscal year in accordance with the Financial Accounting Standards Board, or FASB, Accounting Standards Codification Topic 718 for stock-based compensation. These amounts do not correspond to the actual cash value that will be recognized by the directors when received. Assumptions used in the calculation of the amounts in this column are included in note 11 to our audited consolidated financial statements included in our 2024 Annual Report on Form 10-K. As of December 31, 2024, the following directors had the following numbers of options outstanding